title: [Clinical observation of transcatheter uterine artery embolization for uterine myoma].
abstract: OBJECTIVE
  To investigate the efficiency and safety of transcatheter uterine artery embolization (TUAE) for uterine myomas.
  
  
  METHODS
  Thirty-eight cases of uterine myomas were treated by TUAE using lipiodol-pingyangmycin emulsion. 5 of 38 cases underwent hysterectomy or myomectomy from 1 to 3 weeks after TUAE. The specimens were studied pathologically. Thirty-three of 38 patients were followed for 3 to 6 months to observe the changes of myoma size and uterine volume and overian function.
  
  
  RESULTS
  Symptom released in 90.6% (29/32), that was controlled of menorrhagia in 90.3% (28/31), disappeared of lumbago and lower abdominal pain in 83.3% (25/30), relieved of freguency and urgency of micturition in 45.5% (5/11). The mean reduction of myoma and uterine volume at 6 months was 59.1% and 49.3%, respectively, and at 12 months was 61.8% and 49.9% respectively. There was no significant difference in hormone level pre-embolization and post-embolization. Pathological studies of specimens showed that lipiodol deposition was found in myomas but not in myometrium. Myomas occurred spotty necrosis 2 weeks after embolization and extensive patchy necrosis 3 weeks after embolization. Degeneration or necrosis were not seen in myometrium.
  
  
  CONCLUSIONS
  TUAE possesses a good effect for uterine myomas and doesn't result in the damage of ovarian hormone secretion and the myometrium.
authors.affiliation: Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Du
authors.forename: Yuewei
authors.initials: Y
authors.lastname: Zuo
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Chen
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Hu
authors.forename: Huahuan
authors.initials: H
authors.lastname: Lin
authors.forename: Pengfei
authors.initials: P
authors.lastname: Luo
authors.forename: Danhua
authors.initials: D
authors.lastname: Hong
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000627:therapeutic use; D007889:Leiomyoma / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D009336:Necrosis; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007459:Iodized Oil